Did the patients’ tiredness reduce or worsen?
Patients were asked to complete a questionnaire designed to understand how tiredness is affecting
their quality of life. The researchers compared the results from the beginning of the study to the
end of 36 or 40 weeks of treatment.
Patients in all 4 groups reported feeling less tired. Patients in Group 3 had
the greatest improvement in tiredness levels.
Did ravulizumab improve the patients’ overall quality of life?
Each patient rated their health, ability to function, and symptoms of PNH on a questionnaire.
The researchers compared the scores from the beginning of the study to the end of 36 or
40 weeks of treatment.
Patients in all 4 groups had improved health, ability to function, and
symptoms of PNH.
Summary of answers:
Following 36 to 40 weeks of treatment, all 4 dosing regimens of ravulizumab:
• Lowered the patients’ LDH level
• Reduced hemolysis
• Reduced the need for a blood transfusion in some patients
• Improved the patients’ common symptoms of PNH
• Reduced the patients’ tiredness levels
• Improved the patients’ overall quality of life
Protocol, ALXN1210-PNH-201 SPONSOR CONTACT INFORMATION:
Europe, 2015-002674-20 1-888-765-4747
© Certara USA, Inc. 2020. All rights reserved United States, NCT02605993 medinfo@alexion.com 8